Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-02-05 Director's Dealing
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Issue of Equity and Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement. The content explicitly discusses the 'Issue of Deferred Consideration Shares' to the CEO and the resulting change in his shareholding percentage. This directly relates to changes in ownership or capital structure involving existing shares, specifically triggered by performance milestones. This falls under the category of reporting changes in significant share ownership or capital structure events. While it involves director dealings (insider transaction), the primary focus is the issuance of shares as deferred consideration and the resulting total share count, which aligns closely with 'Share Issue/Capital Change' (SHA) or potentially 'Director's Dealing' (DIRS). However, the core event is the issuance of new shares (4,591,400 new ordinary shares) as part of a prior agreement, making SHA the most precise fit for the capital structure change aspect. Since it is a formal regulatory news service (RNS) announcement detailing a share issuance, SHA is appropriate. If it were purely about the CEO trading existing shares, DIRS would be better, but this is an issuance event.
2018-02-05 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is clearly identified as originating from 'RNS Number : 8355D' and contains the header 'The company news service from the London Stock Exchange'. The content announces the 'Exercise of Warrants and Total Voting Rights' and the resulting change in the total number of ordinary shares in issue, which directly impacts shareholder voting rights and disclosure thresholds under the FCA's Disclosure and Transparency Rules. This type of announcement, which is a regulatory filing but specifically concerns changes in share capital/voting rights, fits best under the 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if it were about ownership thresholds being crossed. However, the core event is the issuance of new shares via warrant exercise, leading to a change in total shares. Since the document details the exact number of new shares issued and the resulting total shares, 'SHA' (Share Issue/Capital Change) is the most precise fit among the options, although 'RNS' (General Regulatory Filing) is also applicable as a fallback. Given the specific nature of the capital change announcement, SHA is preferred over the general RNS category. The document length (3176 chars) is not indicative of a full report, but this is a specific announcement, not just a notice of publication.
2018-02-02 English
Award of Grant and Collaboration with MedImmune UK
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated February 2, 2018. It announces an 'Award of Grant' and a 'Collaboration with MedImmune UK' funded by Innovate UK. This type of announcement, detailing a specific, material, non-financial event (like a grant award or collaboration) released via the Regulatory News Service (RNS), fits best under the general 'Regulatory Filings' category, as it does not specifically match definitions for earnings (ER), capital changes (CAP), director dealings (DIRS), or dividend notices (DIV). Since it is a formal regulatory announcement disseminated through the RNS system, RNS is the most appropriate classification.
2018-02-02 English
Exercise of Warrants and Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces the exercise of warrants, the resulting issuance of new ordinary shares, and the resulting total voting rights figure. This type of announcement, which relates to changes in the number of shares in issue and voting rights, is a standard regulatory disclosure. While it involves share capital changes (potentially SHA or POS), the primary focus and format align perfectly with a general regulatory announcement disseminated via the RNS system. Given the options, RNS (Regulatory Filings) is the most appropriate general category for a standard, non-specific regulatory update disseminated through the RNS service, especially when it doesn't fit perfectly into the more specific categories like DIV, SHA, or DIRS. The document length is short (3174 chars), but it is the primary announcement itself, not an announcement *about* another report, so RPA is less likely than RNS.
2018-01-30 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number : 8396C' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content explicitly announces the 'Exercise of Warrants and Total Voting Rights' and the subsequent application for admission of new ordinary shares to trading on AIM. This announcement directly relates to a change in the total number of shares in issue and voting rights, which is a specific corporate action announcement. While it involves share capital changes, the primary focus is the notification of the resulting total voting rights figure for shareholders to use under FCA rules. This type of mandatory disclosure, often short and focused on a specific event, fits best under the general 'Regulatory Filings' category (RNS) as it is not a comprehensive report (like 10-K or IR) or a specific capital change announcement (like SHA or POS, which usually announce the *intent* to issue/buy back shares, not the final result of warrant exercise impacting voting rights denominator). Given the explicit RNS branding and the nature of the disclosure (voting rights denominator update), RNS is the most appropriate general regulatory filing code.
2018-01-24 English
Global Business Accelerator Programme in Japan
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated January 24, 2018. The content announces that N4 Pharma Plc has been chosen to attend the Global Business Accelerator Programme Visit to Japan, funded by Innovate UK. This is a specific, non-financial operational update or corporate news item released via the Regulatory News Service (RNS). Since it is a general regulatory announcement that doesn't fit into specific categories like ER, 10-K, or DIV, and it is clearly marked as an RNS release, the most appropriate classification is Regulatory Filings (RNS). The document length (3951 chars) is substantial enough that it is not just a brief announcement of a report, but the report itself detailing the news.
2018-01-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.